Biotech Investment Analyst — Drug Asset & Company Assessment
$120–200/hr
Remote — US-based or deep US-market experience
Contract · Remote
3 mo ago
About the work
Mercor is partnering with a biotech and pharma research team on expert human-evaluation work — creating and critiquing rubrics that analyze commercial drugs and drug-development programs. We're seeking a biotech investment analyst (specialist-fund background) for a paid pilot, with the potential to continue as the work scales. **Responsibilities** - Create and critique rubrics that analyze commercial drugs and drug-development programs - Provide overall company and asset assessment — mechanism, clinical data, competitive position, and value drivers - Judge the quality of an investment-style thesis and flag weak, overconfident, or missing assumptions - Apply your assessment across the pilot's set of companies (~5–10) **Requirements** - US-based biotech / healthcare investment analyst with a specialist-fund background - Familiarity with biotech/pharma development programs - Able to assess a drug asset and the company behind it end-to-end - 5+ years evaluating biotech/pharma companies or assets **Engagement Details** - Duration: Approximately 10–20 hours over a 1–2 week pilot - Remote — US-based **Why Participate** - Help improve expert AI evaluation of drugs and drug-development programs - Recurring engagement for strong contributors
Good fit if you have
- • Any-level experience in Research, Evaluation & Rating, Healthcare & Medicine, Finance & Business, Science & Mathematics
- • Fluency in English
- • A reliable laptop and internet connection
- • Comfort writing clear, structured explanations
Applying is free. Shared links open this job page, and Apply now uses our referral link when available.
Help us measure outcomes
No name or application details are collected.
